Armistice Capital’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-233,790
Closed -$13.5M – 370
2026
Q2
$13.5M Buy
233,790
+28,766
+14% +$1.65M 0.16% 86
2026
Q1
$12.4M Sell
205,024
-167,442
-45% -$9.8M 0.22% 81
2025
Q4
$20.1M Sell
372,466
-277,267
-43% -$13.3M 0.24% 71
2025
Q3
$29.3M Buy
+649,733
New +$30.3M 0.43% 34
2024
Q3
– Sell
-490,868
Closed -$20.4M – 265
2024
Q2
$20.4M Buy
+490,868
New +$22M 0.26% 66
2023
Q4
– Sell
-529,613
Closed -$30.7M – 311
2023
Q3
$30.7M Buy
529,613
+129,613
+32% +$7.94M 0.47% 42
2023
Q2
$25.6M Buy
+400,000
New +$26.8M 0.37% 53
2022
Q4
– Sell
-600,000
Closed -$42.7M – 202
2022
Q3
$42.7M Sell
600,000
-556,000
-48% -$40.3M 0.74% 36
2022
Q2
$89M Sell
1,156,000
-240,000
-17% -$18.3M 1.55% 12
2022
Q1
$102M Sell
1,396,000
-928,000
-40% -$62.3M 1.97% 9
2021
Q4
$145M Sell
2,324,000
-32,000
-1% -$1.88M 2.37% 4
2021
Q3
$139M Buy
2,356,000
+678,000
+40% +$44.7M 2.36% 4
2021
Q2
$112M Buy
1,678,000
+178,000
+12% +$11.6M 2.01% 6
2021
Q1
$94.7M Buy
1,500,000
+464,000
+45% +$28.9M 2.17% 4
2020
Q4
$64.3M Buy
1,036,000
+36,000
+4% +$2.21M 2.19% 7
2020
Q3
$60.3M Hold
1,000,000
– – 2.19% 8
2020
Q2
$58.8M Buy
1,000,000
+352,000
+54% +$21.1M 2.58% 5
2020
Q1
$36.1M Buy
648,000
+148,000
+30% +$9.05M 2.23% 12
2019
Q4
$32.1M Buy
+500,000
New +$28.6M 1.85% 13

Other funds holding BMY

Armistice Capital's BMY Position: Q3 2026 in Review

Armistice Capital sold out of Bristol-Myers Squibb (BMY) in Q3 2026, closing a stake of 233,790 shares — an estimated $13.5M sold.

Armistice Capital first reported a position in BMY in Q4 2019 and held it in 19 quarters. The position peaked at $145M in Q4 2021. 2,567 funds tracked by Wall St. Rank hold BMY as of Q3 2026.

  • Armistice Capital reported no remaining Bristol-Myers Squibb position as of Q3 2026 after selling out during the quarter.
  • Armistice Capital sold 233,790 Bristol-Myers Squibb shares in Q3 2026, an estimated $13.5M.
  • Armistice Capital first reported a position in Bristol-Myers Squibb in Q4 2019 and held it in 19 quarters.
  • Armistice Capital's Bristol-Myers Squibb position peaked at $145M in Q4 2021.
  • 2,567 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.

Based on Armistice Capital's 13F filing for Q3 2026, filed 16 Nov 2026.